Journal of Hepatology
Volume 49, Issue 4 , Pages 652-657 , October 2008

Statements from the Taormina expert meeting on occult hepatitis B virus infection

  • Giovanni Raimondo

      Affiliations

    • Unit of Clinical and Molecular Hepatology, Department of Internal Medicine, Messina University Hospital, Messina, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 0 90 2212392; fax: +39 0 90 935162.
    • ,
  • Jean-Pierre Allain

      Affiliations

    • Department of Haematology, Division of Transfusion Medicine, Cambridge Blood Centre, University of Cambridge, Cambridge, UK
    • ,
  • Maurizia R. Brunetto

      Affiliations

    • Gastroenterology and Hepatology Unit, University Hospital of Pisa, Pisa, Italy
    • ,
  • Marie-Annick Buendia

      Affiliations

    • Unité d’Oncogenèse et Virologie Moléculaire and PT Puce à ADN, Institut Pasteur, Paris, France
    • ,
  • Ding-Shinn Chen

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Massimo Colombo

      Affiliations

    • First Division of Gastroenterology, A.M.& A. Migliavacca Center for Liver Diseases, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    • ,
  • Antonio Craxì

      Affiliations

    • Gastroenterology and Hepatology, Di.Bi.M.I.S., University of Palermo, Palermo, Italy
    • ,
  • Francesco Donato

      Affiliations

    • Institute of Hygiene, Epidemiology and Public Health, University of Brescia, Brescia, Italy
    • ,
  • Carlo Ferrari

      Affiliations

    • Unit of Infectious Diseases and Hepatology, Laboratory of Viral Immunopathology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
    • ,
  • Giovanni B. Gaeta

      Affiliations

    • Department of Infectious Diseases, Second University of Naples, Naples, Italy
    • ,
  • Wolfram H. Gerlich

      Affiliations

    • Institute of Medical Virology, Justus Liebig University, Giessen, Germany
    • ,
  • Massimo Levrero

      Affiliations

    • Department of Internal Medicine and Laboratory of Gene Expression, Fondazione Andrea Cesalpino, University of Rome “La Sapienza”, Rome, Italy
    • ,
  • Stephen Locarnini

      Affiliations

    • Research and Molecular Development,Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    • ,
  • Thomas Michalak

      Affiliations

    • Molecular Virology and Hepatology Research Group, Division of BioMedical Science, and Discipline of Laboratory Medicine, Faculty of Medicine, Health Science Centre, Memorial University, St. John’s, Newfoundland, Canada
    • ,
  • Mario U. Mondelli

      Affiliations

    • Area Infettivologica,Fondazione IRCCS Policlinico S. Matteo and Dipartimento di Malattie Infettive, University of Pavia, Pavia, Italy
    • ,
  • Jean-Michel Pawlotsky

      Affiliations

    • Department of Virology, French National Reference Center for Viral Hepatitis B, C and delta, and INSERM U841, Hôpital Henri Mondor, Université Paris XII, Créteil, Paris, France
    • ,
  • Teresa Pollicino

      Affiliations

    • Unit of Clinical and Molecular Hepatology, Department of Internal Medicine, Messina University Hospital, Messina, Italy
    • ,
  • Daniele Prati

      Affiliations

    • First Division of Gastroenterology, A.M.& A. Migliavacca Center for Liver Diseases, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    • Department of Transfusion Medicine and Hematology, A. Manzoni Hospital, Lecco, Italy
    • ,
  • Massimo Puoti

      Affiliations

    • Institute of Hygiene, Epidemiology and Public Health, University of Brescia, Brescia, Italy
    • ,
  • Didier Samuel

      Affiliations

    • Hôpital Paul Brousse, Centre Hépato-Biliaire, Université Paris-Sud, UMR-S 785, INSERM U785, Villejuif, France
    • ,
  • Daniel Shouval

      Affiliations

    • Liver Unit, Hadassah-Hebrew University Hospital, Jerusalem, Israel
    • ,
  • Antonina Smedile

      Affiliations

    • Department of Gastro-Hepatology, San Giovanni Battista (Molinette) Hospital, Turin, Italy
    • ,
  • Giovanni Squadrito

      Affiliations

    • Unit of Clinical and Molecular Hepatology, Department of Internal Medicine, Messina University Hospital, Messina, Italy
    • ,
  • Christian Trépo

      Affiliations

    • INSERM, U871, 26 Université Claude Bernard Lyon 1, Lyon, Hospices Civils de Lyon, Hôtel Dieu, Service d’Hépatologie, Lyon, France
    • ,
  • Erica Villa

      Affiliations

    • Department of Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy
    • ,
  • Hans Will

      Affiliations

    • Heinrich-Pette-Institut für experimentelle Virologie und Immunologie an der Universität Hamburg, Hamburg, Germany
    • ,
  • Alessandro R. Zanetti

      Affiliations

    • First Division of Gastroenterology, A.M.& A. Migliavacca Center for Liver Diseases, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    • ,
  • Fabien Zoulim

      Affiliations

    • INSERM, U871, 26 Université Claude Bernard Lyon 1, Lyon, Hospices Civils de Lyon, Hôtel Dieu, Service d’Hépatologie, Lyon, France

References 

  1. McMahon BJ. Chronic carriers of hepatitis B virus who clear hepatitis B surface antigen: are they really “off the hook?. Hepatology. 1998;28:265–267
  2. Michalak TI. Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model. Immunol Rev. 2000;174:98–111
  3. Raimondo G, Balsano C, Craxì A, Farinati F, Levrero M, Mondelli M, et al. Occult hepatitis B virus infection. Dig Liver Dis. 2000;32:822–826
  4. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely occult?. Hepatology. 2001;34:194–203
  5. Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: a hidden menace?. Hepatology. 2001;34:204–206
  6. Raimondo G. Occult hepatitis B virus infection and liver disease: fact or fiction?. J Hepatol. 2001;34:471–473
  7. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2:479–486
  8. Munoz SJ. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl. 2002;8:S82–S87
  9. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat. 2002;9:243–257
  10. Blendis L, Lurie Y, Oren R. Occult HBV infection – both hidden and mysterious. Gastroenterology. 2003;125:1903–1905
  11. Bowden S, Bartholomeusz A, Locarnini S. Lamivudine resistant occult HBV: implications for public health?. J Hepatol. 2003;38:526–528
  12. Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang. 2004;86:83–91
  13. Marrero JA, Lok AS. Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit?. Gastroenterology. 2004;126:347–350
  14. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 2004;127:S56–S61
  15. Chemin I, Trepo C. Clinical impact of occult HBV infections. J Clin Virol. 2005;34:S15–S21
  16. Chen CJ. Time-dependent events in natural history of occult hepatitis B virus infection: the importance of population-based long-term follow-up study with repeated measurements. J Hepatol. 2005;42:438–440
  17. Raimondo G, Pollicino T, Squadrito G. What is the clinical impact of occult hepatitis B virus infection?. Lancet. 2005;365:638–640
  18. Gerlich W, Wagner F, Chudy M, Harritshoj L, Lattermann A, Wienzek S, et al. HBsAg non-reactive HBV infection in blood donors: transmission and pathogenicity. J Med Virol. 2006;79:S32–S36
  19. Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12–14, 2006). J Hepatol. 2006;45:127–143
  20. Weber B. Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. J Med Virol. 2006;78:S59–S65
  21. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–220
  22. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol. 2006;44:S65–S70
  23. Donato F, Gelatti U, Limina RM, Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene. 2006;25:3756–3770
  24. Comanor L, Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox Sang. 2006;91:1–12
  25. Zanetti AR, Romano L, Zappa A, Velati C. Changing patterns of hepatitis B infection in Italy and NAT testing for improving the safety of blood supply. J Clin Virol. 2006;36:S51–S55
  26. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46:160–170
  27. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699–712
  28. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39:397–408
  29. Gerlich WH, Glebe D, Schuttler CG. Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus. J Viral Hepat. 2007;14:16–21
  30. Mulrooney-Cousins PM, Michalak TI. Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J Gastroenterol. 2007;13:5682–5686
  31. Shouval D. What is the clinical significance of the high prevalence of occult hepatitis B in US liver transplant patients with chronic hepatitis C?. Liver Transpl. 2008;14:418–419
  32. Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion. 2008;48:1001–1026
  33. Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, et al. Long-lasting memory T-cell responses following self-limited acute hepatitis B. J Clin Invest. 1996;98:1185–1194
  34. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest. 1994;93:230–239
  35. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996;10:1104–1108
  36. Yotsuyanagi H, Yasuda K, Iino S, Moriya K, Shintani Y, Fujie H, et al. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology. 1998;27:1377–1382
  37. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341:22–26
  38. Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123:1084–1089
  39. Huo TI, Wu JC, Lee PC, Chau GY, Lui WY, Tsay SH, et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology. 1998;28:231–236
  40. Michalak TI, Mulrooney PM, Coffin CS. Low doses of hepadnavirus induce infection of the lymphatic system that does not engage the liver. J Virol. 2004;78:1730–1738
  41. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology. 1998;27:1736–1742
  42. Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology. 2000;31:488–495
  43. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxì A, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004;126:102–110
  44. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol. 2005;42:302–308
  45. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750–1758
  46. Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology. 2007;45:277–285
  47. Vivekanandan P, Kannangai R, Ray SC, Thomas DL, Torbenson M. Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis. 2008;46:1227–1236
  48. Blum H, Galun E, Liang TJ, von Weizsacker F, Wands JR. Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication. J Virol. 1991;65:1836–1842
  49. Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease full-length genome and analysis of mutant surface promoter. Gastroenterology. 2004;127:1356–1371
  50. Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P, et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology. 2008;134:1470–1481
  51. Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol. 2008;48:743–746
  52. Cougot D, Neuveut C, Buendia MA. HBV induced carcinogenesis. J Clin Virol. 2005;34:S75–S78
  53. Shetty K, Hussain M, Nei L, Reddy KR, Lok AS. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl. 2008;14:534–540

☆ The participants at this meeting declare that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this meeting report.

PII: S0168-8278(08)00479-0

doi: 10.1016/j.jhep.2008.07.014

Journal of Hepatology
Volume 49, Issue 4 , Pages 652-657 , October 2008

Article Tools

* Image Usage & Resolution